

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Neither this announcement nor any copy thereof may be released into or distributed directly or indirectly in the United States or any other jurisdiction where such release or distribution might be unlawful.

This announcement is for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.

This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 (the “US Securities Act”), and may not be offered or sold in the United States unless registered under the US Securities Act or pursuant to an exemption from, or in a transaction not subject to, registration under the US Securities Act. The Company has no intention to register under the US Securities Act any of the securities referred to herein or to conduct a public offering of securities in the United States.



創勝集團醫藥有限公司

Transcenta Holding Limited

(registered by way of continuation in the Cayman Islands with limited liability)

(Stock Code: 6628)

COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE

Sole Overall Coordinator, Sole Global Coordinator, Sole Placing Agent



Reference is made to the announcement of the Company dated September 10, 2025 in respect of the placing of new Shares under the General Mandate (the “**Announcement**”). Unless defined otherwise, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Board announces that all the conditions of the Placing have been fulfilled and the completion of the Placing took place on September 17, 2025 (the “**Completion**”). An aggregate of 14,400,000 Placing Shares have been successfully placed by the Placing Agent to not fewer than six Placees at the Placing Price of HK\$4.33 per Share pursuant to the terms and conditions of the Placing Agreement. To the best of the Directors’ knowledge, information and belief and having made all reasonable enquiries, the Placees and their respective ultimate beneficial owners are Independent Third Parties.

The net proceeds from the Placing amount to approximately HK\$59.34 million. For further details on the use of proceeds, please refer to the Announcement.

The Placing Shares are issued under the General Mandate granted to the Directors pursuant to an ordinary resolution passed by the Shareholders of the Company at the annual general meeting of the Company held on June 6, 2025 to allot, issue and deal with up to 86,969,089 Shares. Immediately prior to the Placing, the number of new Shares that could be allotted and issued by the Company under the General Mandate was 86,969,089 Shares (including any sale or transfer of Shares out of treasury that are held as treasury Shares). Following the Completion, the Company may still allot, issue and deal with up to 72,569,089 Shares pursuant to the General Mandate.

EFFECTS ON SHAREHOLDING STRUCTURE OF THE COMPANY

To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, the following table sets out the shareholding structure of the Company (excluding treasury Shares) (i) as at the date of the Announcement; and (ii) immediately upon Completion:

Shareholder	As at the date of the Announcement		Immediately upon Completion	
	Number of Shares	Approximate %	Number of Shares	Approximate %
<i><u>Directors</u></i>				
Dr. Xueming Qian ⁽¹⁾	29,607,788	6.81%	29,607,788	6.59%
Dr. Li Xu	1,339,525	0.31%	1,339,525	0.30%
<i><u>Substantial Shareholders</u></i>				
Yi Shi ⁽²⁾	70,536,703	16.21%	70,536,703	15.69%
HSBC Trust Company (Delaware) National Association ⁽¹⁾	22,411,376	5.15%	22,411,376	4.99%
<i><u>Public Shareholders</u></i>				
– The Placees	–	–	14,400,000	3.20%
– Other public Shareholders	311,179,717	71.52%	311,179,717	69.23%
Total	435,075,109	100.00%	449,475,109	100.00%

Notes:

1. This includes 23,242,154 Shares held by Qian Dynasty Irrevocable Trust, in which the beneficiaries are Dr. Xueming Qian and his children and their descendants, the investment advisor is Dr. Qian and the trustee is HSBC Trust Company (Delaware) National Association. In addition, HSBC Trust Company (Delaware) National Association is interested 22,411,376 Shares held by Ms. Xiaohong Shi. Ms. Xiaohong Shi is the investment adviser of Shi Dynasty Irrevocable Trust and has control of the voting rights attached to the relevant Shares. The trustee of Shi Dynasty Irrevocable Trust is HSBC Trust Company (Delaware) National Association.

2. LAV Biosciences Fund III, L.P. and Lilly Asia Ventures Fund III, L.P. are Cayman Islands exempted partnership funds. The general partner of LAV Biosciences Fund III, L.P. and Lilly Asia Ventures Fund III, L.P. are LAV GP III, L.P., whose general partner is LAV Corporate GP, Ltd., a Cayman exempted company wholly owned by Yi Shi. Both LAV Vitality Limited (beneficial owner of 22,388,232 Shares) and LAV Altitude Limited (beneficial owner of 10,276,020 Shares) are limited companies incorporated in the British Virgin Islands and are wholly-owned by LAV Biosciences Fund III, L.P. LAV Biosciences Fund III, L.P. also holds 1,046,711 Shares in its own name. Both LAV Verdure Limited (beneficial owner of 11,194,116 Shares) and LAV Acuity Limited (beneficial owner of 5,138,010 Shares) are limited companies incorporated in the British Virgin Islands and are wholly-owned by Lilly Asia Ventures Fund III, L.P.. Lilly Asia Ventures Fund III, L.P. also holds 523,047 Shares in its own name.

LAV Biosciences Fund V, L.P. is a Cayman Islands exempted partnership fund. The general partner of LAV Biosciences Fund V, L.P. is LAV GP V, L.P., whose general partner is LAV Corporate V GP, Ltd., a Cayman exempted company wholly owned by Yi Shi. LAV Biosciences Fund V, L.P. holds 16,667,067 Shares in its own name and wholly-owns LAV Amber Limited, which is the beneficial owner of 3,303,500 Shares.

LAV Asset Management (Hong Kong) Limited has entered into an investment management agreement to manage Shares held by the funds. Therefore, each of Yi Shi and LAV Asset Management (Hong Kong) Limited is deemed to be interested in the Shares held by LAV Biosciences Fund III, L.P., LAV Vitality Limited, LAV Altitude Limited, Lilly Asia Ventures Fund III, L.P., LAV Verdure Limited, LAV Acuity Limited, LAV Biosciences Fund V, L.P. and LAV Amber Limited.

3. The above table assumes no Shares have been issued or purchased by the Company between the date of the Announcement and Completion, save for the allotment and issue of the Placing Shares.

By Order of the Board
Transcenta Holding Limited
Xueming Qian

Executive Director, Chairman and Chief Executive Officer

Hong Kong, September 17, 2025

As at the date of this announcement, the board of directors of the Company comprises Dr. Xueming Qian as executive Director, chairman and chief executive officer, Dr. Li Xu as non-executive Director and Mr. Jiasong Tang, Mr. Zhihua Zhang, Dr. Kumar Srinivasan and Ms. Helen Wei Chen as independent non-executive Directors.